Companies · TARS · Biological Products, (No Diagnostic Substances)

Tarsus Pharmaceuticals, Inc. (TARS)

Every material event, decoded in plain English — what each one means for the stock.

Raises $125 million ahead of Alkeus merger, with near-term dilution

XDEMVY sales beat expectations, but heavier spending drove a sharp EPS miss

Tarsus buys a Phase 3 Stargardt asset, with data still years away

Open live on AllSight — the whole market, decoded →